Akoya Biosciences (AKYA) Set to Announce Quarterly Earnings on Thursday

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, November 14th. Analysts expect Akoya Biosciences to post earnings of ($0.19) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last issued its earnings results on Monday, August 5th. The company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). Akoya Biosciences had a negative return on equity of 126.38% and a negative net margin of 64.74%. The company had revenue of $23.16 million during the quarter, compared to the consensus estimate of $23.61 million. During the same period last year, the business posted ($0.51) EPS. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Stock Performance

AKYA stock traded down $0.02 during midday trading on Thursday, hitting $3.22. The company's stock had a trading volume of 108,300 shares, compared to its average volume of 223,458. The company has a quick ratio of 1.98, a current ratio of 2.73 and a debt-to-equity ratio of 3.43. The stock's 50-day moving average price is $2.82 and its 200 day moving average price is $2.68. Akoya Biosciences has a 1 year low of $1.88 and a 1 year high of $6.31. The stock has a market cap of $159.39 million, a price-to-earnings ratio of -2.63 and a beta of 1.34.

Wall Street Analyst Weigh In

A number of research analysts have commented on AKYA shares. Morgan Stanley lowered Akoya Biosciences from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $4.00 to $3.00 in a research report on Tuesday, August 6th. JPMorgan Chase & Co. downgraded shares of Akoya Biosciences from an "overweight" rating to a "neutral" rating in a report on Tuesday, August 6th. Craig Hallum decreased their target price on shares of Akoya Biosciences from $7.50 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. BTIG Research lowered shares of Akoya Biosciences from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. Finally, Piper Sandler lowered their price target on Akoya Biosciences from $6.00 to $4.00 and set an "overweight" rating for the company in a report on Tuesday, August 13th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $6.56.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.